Telomir Pharmaceuticals, Inc. Common Stock (TELO) - Total Assets
Based on the latest financial reports, Telomir Pharmaceuticals, Inc. Common Stock (TELO) holds total assets worth $5.79 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Telomir Pharmaceuticals, Inc. Common Stock - Total Assets Trend (2021–2025)
This chart illustrates how Telomir Pharmaceuticals, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see Telomir Pharmaceuticals, Inc. Common Sto stock valuation for the company's overall valuation and market capitalisation.
Telomir Pharmaceuticals, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (September 2025)
Telomir Pharmaceuticals, Inc. Common Stock's total assets of $5.79 Million consist of 100.0% current assets and 0.0% non-current assets. Review total liabilities of Telomir Pharmaceuticals, Inc. Common Sto to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 99.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Telomir Pharmaceuticals, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Telomir Pharmaceuticals, Inc. Common Sto stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Telomir Pharmaceuticals, Inc. Common Stock's current assets represent 100.0% of total assets in 2025, an increase from 0.0% in 2021.
- Cash Position: Cash and equivalents constituted 99.3% of total assets in 2025, up from 0.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Telomir Pharmaceuticals, Inc. Common Stock Competitors by Total Assets
Key competitors of Telomir Pharmaceuticals, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Telomir Pharmaceuticals, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.00 | 0.75 | 0.05 |
| Quick Ratio | 7.00 | 0.75 | 0.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.96 Million | $-161.11K | $-937.28K |
Telomir Pharmaceuticals, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Telomir Pharmaceuticals, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.24 |
| Latest Market Cap to Assets Ratio | 10.40 |
| Asset Growth Rate (YoY) | 454.5% |
| Total Assets | $7.34 Million |
| Market Capitalization | $76.34 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Telomir Pharmaceuticals, Inc. Common Stock's assets at a significant premium (10.40x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Telomir Pharmaceuticals, Inc. Common Stock's assets grew by 454.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Telomir Pharmaceuticals, Inc. Common Stock (2021–2025)
The table below shows the annual total assets of Telomir Pharmaceuticals, Inc. Common Stock from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $7.34 Million | +454.48% |
| 2024-09-30 | $1.32 Million | -72.26% |
| 2023-09-30 | $4.77 Million | +9696.36% |
| 2022-09-30 | $48.73K | -11.40% |
| 2021-09-30 | $55.00K | -- |
About Telomir Pharmaceuticals, Inc. Common Stock
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macu… Read more